Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Suresh S. Ramalingam(Emory University), Gabriel Sica(Emory University), Bradley W. Lash(SUNY Upstate Medical University), James L. Wade(American Society of Clinical Oncology), Charu Aggarwal(UPMC Hillman Cancer Center), Gordan Srkalović(Regional Cancer Center), Lynne I. Wagner(University of North Carolina at Chapel Hill), Joseph W. Leach(Minnesota Oncology), Ticiana B. Leal(University of Wisconsin–Madison), Suzanne E. Dahlberg(Dana-Farber Cancer Institute)
Cited by 193
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k